|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer.<b>Experimental Design:</b> By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, <i>in vitro</i> macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer.<b>Results:</b> Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages.
|
30012567 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Role of Tumor Suppressor DLC-1: Far From Clear.
|
27604574 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 has been identified as a candidate tumor suppressor.
|
27366946 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DLC-1 expression was not found to be associated with tumor differentiation status.
|
26514520 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 inhibits cell growth and invasion in human colon cancer, functioning as a tumor-suppressor gene, possibly through the regulation of the Wnt/β-catenin signaling pathway.
|
24604602 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 is a tumor suppressor gene frequently silenced in human cancers.
|
23509688 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells.
|
23588806 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since DLC‑1 is a candidate tumor suppressor gene, we sought to determine whether DLC‑1 expression is associated with cell proliferation in colon cancer cell lines.
|
23783552 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.
|
20882354 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostates of the TG mice showed an increased size and changes in stromal and epithelial morphology progressing from atypia and prostatic intraepithelial neoplasia (mouse PIN, mPIN) lesions to tumors with highly variable phenotype bearing features of adenocarcinoma, carcinosarcoma, and sarcoma.
|
21076617 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Restoration of DLC-1 expression in RCC cells led to Bcl-2 and caspase-3 mediated apoptosis as well as attenuated the ability of the cells to form RCC tumors in athymic nude mice (P<0.05).
|
19380190 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 is a multi-domain protein that includes a Rho GTPase activating protein (RhoGAP) domain which has been hypothesized to be the basis of its tumor suppressive actions.
|
17932950 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer-1) is a potential tumor suppressor gene, which is inactive in liver carcinogenesis.
|
18288400 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1:a Rho GTPase-activating protein and tumour suppressor.
|
17979893 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer-1) is a tumor suppressor gene for hepatocellular carcinoma and other cancers.
|
17292327 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More than a 10-fold increase in mRNA expression was observed for two previously identified tumor suppressor genes (DLC-1 and DCC) and also for RPIB9 and PCDHGA12.
|
17363581 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 that encodes a Rho GTPase-activating protein, functions as a tumor suppressor gene and is frequently inactivated or down-regulated in several common cancers.
|
17418982 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Two related Rho GTPase-activating proteins, DLC-1 (deleted in liver cancer 1) and DLC-2, are emerging as bona fide tumor suppressor genes that inhibit cancer cell growth.
|
17297465 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The methylation of the candidate tumor suppressor gene DLC-1 was detected in a high proportion of primary tumor and plasma DNA samples by using quantitative methylation-specific PCR analysis.
|
16774933 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results suggest that DLC-1 might be an NPC-related tumor suppressor gene affected by aberrant promoter methylation and gene deletion.
|
16680376 |
2006 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
|
17016643 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to evaluate whether DLC-1, a newly identified tumor-suppressor gene on chromosome 8p22, is involved in the tumorigenesis of MBs and the histologically similar SPNETs.
|
15712180 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the current study, the subcellular localization of Dlc-1 protein was determined by immunostaining with antibody to DLC-1 and the possible tumor growth suppressor activity of DLC-1 was investigated by examining the effects of of DLC-1 cDNA transfection in two human HCC cell lines lacking expression of the endogenous gene.
|
14647417 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.
|
14661059 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Absence or low expression of DLC-1, a tumor suppressor gene, in breast cancers has been shown recently.
|
15201975 |
2004 |